Harmony Biosciences Holdings vs Prestige Consumer Healthcare
Prestige Consumer Healthcare is the larger business, with $1.09bn of revenue in fiscal 2026 against $868m for Harmony Biosciences Holdings (1.3 times as much). Harmony Biosciences Holdings grew faster (21.5% against -4.3%). Harmony Biosciences Holdings kept more of each dollar of sales as profit: a net margin of 18.3% against 17.5%.
| Latest fiscal year | Harmony Biosciences HoldingsHRMY, 2025 | Prestige Consumer HealthcarePBH, 2026 |
|---|---|---|
| Revenue | $868m | $1.09bn |
| Revenue growth | 21.5% | -4.3% |
| Net income | $159m | $190m |
| Operating margin | 24.0% | — |
| Net margin | 18.3% | 17.5% |
| Return on equity | 20.8% | 10.2% |
| Free cash flow | $348m | $246m |
| Cash | $753m | $63.9m |
| Total debt | $165m | $1.00bn |
| Debt to equity | 19.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $156m |
| Employees | 293 | 890 |
| Market value | $2.14bn | $2.34bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 93 (Strong) | 67 (Moderate) |
| Insider trades, 12 months | 0 buys, 13 sales | 0 buys, 8 sales |